PharmAccess African Studies to Evaluate Resistance - Monitoring Study (PASER-M)

Sample details

PASER-M assesses the prevalence and incidence of HIV drug resistance, mutational patterns, and factors in persons initiating anti-retroviral therapy (ART) in Kenya, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe. Recruited participants were at least 18 years old and eligible for first-line ART. At baseline, over 2,800 participants were included in the study. Participants were followed up every 3 months.

Study design
Cohort - clinical

Number of participants at first data collection

2,895 (participants)

Age at first data collection

≥ 18 years (participants)

Participant year of birth

Varied (participants)

Participant sex
All

Representative sample at baseline?
No

Sample features

Adults

Patients and clinical populations

People living with HIV

Dataset details

Loading map...

Countries

Kenya, Nigeria, South Africa, Uganda, Zambia

Year of first data collection

2007

Primary Institutions

Amsterdam Institute for Global Health and Development (AIGHD) (Research, Netherlands)

Coptic Hope Center (Healthcare/Medical, Zambia)

Institute of Human Virology Nigeria (IHVN) (Research, Nigeria)

Lagos University Teaching Hospital (LUTH) (Academic, Nigeria)

Lusaka Trust Hospital (Healthcare/Medical, Zambia)

Links

aighd.org/project/paser/

Profile paper DOI

doi.org/10.1093/ije/dyq192

Funders

African partnership for capacity development and clinical interventions against poverty-related diseases (NACCAPII): ART-A phase I, ART-A phase II (Research, South Africa)

Embassy of the Kingdom of the Netherlands in Pretoria Regional HIV/AIDS Program (Government, South Africa)

Heineken Africa Foundation (Third Sector, Netherlands)

Jura Foundation (Third Sector, United Kingdom)

Ministry of Foreign Affairs (Government, Netherlands)

Ongoing?
No

Data types collected